Table 4.

Cox proportional hazards models in 199 patients who received C-SLED

Variable	No. of Patients	HR (95% CI)	P Value
Univariate
Age	199	0.999 (0.988–1.009)	0.83
Sex (female vs. male)	199	0.84 (0.58–1.22)	0.37
Primary cancer (solid vs. hematologic)	199	0.83 (0.58–1.18)	0.29
BMI	198	0.98 (0.96–1.007)	0.18
C-SLED duration	199	0.998 (0.996–1)	0.07
SOFA score	199	1.12 (1.07–1.18)	0.0001
BUNa	199	0.997 (0.98–1.01)	0.65
Serum creatininea	199	0.8 (0.66–0.98)	0.03
Serum albumina	199	0.68 (0.51–0.92)	0.01
Serum magnesiuma	199	1.31 (0.76–2.24)	0.33
Serum phosphatea	199	1.20 (1.08–1.33)	0.0005
Serum potassiuma	199	2.05 (1.48–2.84)	0.0001
Serum ionized calciuma	199	1 (0.81–1.24)	1.00
Blood pHa	199	0.001 (0–0.007)	0.0001
MAPa	199	0.97 (0.96–0.98)	0.0001
BUN at start of C-SLED	196	1.002 (0.996–1.007)	0.53
Serum creatinine at start of C-SLED	197	0.83 (0.73–0.94)	0.004
Serum albumin at start of C-SLED	167	0.75 (0.58–0.98)	0.035
TPN anytime during the first 48 h (yes vs. no)	199	0.62 (0.36–1.06)	0.07
Multivariate
Blood pHa	199	0.005 (0.001–0.04)	<0.0001
MAPa	199	0.98 (0.96–0.99)	0.0002
SOFA Score	199	1.12 (1.07–1.19)	<0.0001
Duration of SLED	199	0.997 (0.995–0.999)	0.004

BMI, body mass index; BUN, blood urea nitrogen; CI, confidence interval; C-SLED, continuous sustained low-efficiency dialysis; HR, hazard ratio; MAP, mean arterial pressure; SOFA, sequential organ failure assessment; TPN, total parenteral nutrition.

^aIndicates fitted as time-dependent variables.